Calgary, Alberta – March 11, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it will be attending and presenting at the Bloom...
Calgary, Alberta – January 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce that the Chinese patent office has issued a notice...
Calgary, Alberta – January 7, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement of common shares of the Company...
Calgary, Alberta – November 26, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share additional data from its ongoing preclinical Rett syndrome...
Calgary, Alberta – November 21, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it has been awarded the Alberta Innovates AICE...
CALGARY, Alberta, Nov. 13, 2024 (GLOBE NEWSWIRE) – Marvel Biosciences Corp.(TSX:V MBCOF:OTC), based in Calgary, Alberta, focused on Alzheimer’s Disease, Depression and Autism today announced that Dr. Mark Williams, CSO will present live at the Life Sciences...
